Capricor Therapeutics, Inc. CAPR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Capricor Therapeutics, Inc. (CAPR) is a healthcare company listed in the US with a market value of about $554M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -60%.
About Capricor Therapeutics
Capricor Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $5M in 2014 to $22M in 2024, growth of about 16.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 89% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22M | $25M | $3M | $244898 | $310250 | $1M | $2M | $3M | $4M |
| Net income | -$105M | -$40M | -$22M | -$29M | -$20M | -$14M | -$8M | -$15M | $2M | -$19M |
| Free cash flow | -$73M | -$41M | -$27M | $3M | -$18M | -$11M | -$7M | -$14M | -$14M | -$15M |
| EPS (diluted) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 | $-0.88 | $-2.06 | $-5.20 | $0.90 | $-10.10 |
| Net margin | — | -181.7% | -88.5% | -1137.4% | -8175.9% | -4401.9% | -760.4% | -908.9% | 91.2% | -470.3% |
| ROIC | -26.7% | -22.9% | -67.4% | -135.1% | -48.3% | -37.9% | -89.3% | -262.3% | -90.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $27.25, 186% above the current price; targets range from $10.50 to $54.00; the consensus rating is “Buy”; expected EPS is $-2.45 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Capricor Therapeutics pay a dividend?
Not currently.
Is Capricor Therapeutics a good stock to buy?
We do not give buy or sell advice. Capricor Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.